Good morning, everyone, and how are you today? We are doing just fine, thank you. Given that this is already the middle of the week and we have survived this far, no reason not to continue, yes? Just consider the alternatives. In fact, this modest accomplishment calls for celebration. So please join us in quaffing a ritual cup of needed stimulation. Our choice today is toasted hazelnut. Or grab a bottle of water, if you prefer. Meanwhile, here are a few items of interest to help you along. Once again, we hope you have a successful day and, of course, keep in touch. We enjoy hearing your tips and tidbits…
The U.S. Food and Drug Administration declined to approve a higher-dose version of a Regeneron Pharmaceuticals drug called Eylea for treating a disease that is the leading cause of blindness among the elderly, Reuters writes. The move comes as Regeneron seeks to defend the blockbuster treatment against a fast-gaining rival. The agency issued a complete response letter that cited issues with a third party company that was contracted to fill the higher dose of the medicine. The letter did not identify any issues with clinical efficacy or safety, trial design, labeling, or drug substance manufacturing, and no additional clinical data or study have been requested.
A year after two major drugmakers sued a wholesaler for its alleged role in distributing counterfeit HIV pills, the U.S. Food and Drug Administration warned the same company for failing to ensure that “suspect” medicines did not enter the marketplace, STAT writes. In a June 8 letter, the agency rebuked Safe Chain Solutions for violating a federal law designed to bolster the integrity of the pharmaceutical supply chain. Gilead Sciences and Johnson & Johnson had filed separate lawsuits accusing Safe Chain — as well as several little-known distributors and pharmacies — of disseminating countless bottles of fake HIV medicines and incorrect pills, including antipsychotics.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect